PPAR激动剂治疗中枢神经系统疾病的研究进展

Research progress of PPAR agonists in central nervous system diseases treatment

过氧化物酶增殖体激活受体（PPAR）是一类调节免疫及炎症反应的核转录因子超家族成员。PPAR-α，PPAR—β／δ和PPAR-1激动剂已被证实在多发性硬化，阿尔兹海默病，帕金森病和脑卒中动物模型中起到抗炎及神经保护作用。PPAR激动剂通过抑制NF—κB，Jak—STAT信号途径的激活及炎症细胞因子的分泌在中枢神经系统疾病的治疗中发挥关键作用。

Peroxisome proliferator-activated receptor belongs to the superfamily of nuclear hormone receptor that regulates immune and inflammatory responses. PPAR α, β/δ and γ agonists have proven effective in the animal models of multiple sclerosis （MS） , Alzbeimer＇ s disease （AD） , Parkinson＇ s disease （ PD ） and stroke, suggesting their use in anti-inflammatory and neuroprotective effects. By inhibiting the activation of NF- κB, Jak-STAT signaling pathways and secretion of inflammatory cytokines, PPAR agonists play an critical effect in the treatment of CNS diseases.